EUVIMEDEUVIMED entdecken
Crossref

Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients

Anahid Hamparsumian, Andrea Sitlinger, Danielle M. Brander

Advances in Oncology · 2026-05 · 6 (1) · 145-163

DOI: 10.1016/j.yao.2026.01.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Oncology, 2026-05. Verfasst von Anahid Hamparsumian und 2 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Hamparsumian, A., Sitlinger, A., & Brander, D. M. (2026). Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients. Advances in Oncology, 6(1), 145-163. https://doi.org/10.1016/j.yao.2026.01.015

Vancouver

Hamparsumian A, Sitlinger A, Brander DM. Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients. Advances in Oncology. 2026;6(1):145-163. doi:10.1016/j.yao.2026.01.015

BibTeX
@article{Hamparsumian2026,
  author = {Hamparsumian, Anahid and Sitlinger, Andrea and Brander, Danielle M.},
  title = {Measurable Residual Disease-Driven Approach to Frontline Treatment for Chronic Lymphocytic Leukemia in Younger and/or Fit Patients},
  journal = {Advances in Oncology},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {145--163},
  doi = {10.1016/j.yao.2026.01.015}
}
Kostenlos starten →